KMT2D and diffuse large B-cell lymphoma: Intriguingly, DLBCL patients also exhibit recurrent loss of KMT2D in combination with EZH2 GOF [20,37], yet the composite effects of these mutations on the epigenetic network and the cancer phenotype are not well understood.